

Jie-Fu Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11317148/publications.pdf>

Version: 2024-02-01

38
papers

999
citations

759233

12
h-index

610901

24
g-index

40
all docs

40
docs citations

40
times ranked

1783
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanostructure Embedded Microchips for Detection, Isolation, and Characterization of Circulating Tumor Cells. <i>Accounts of Chemical Research</i> , 2014, 47, 2941-2950.	15.6	202
2	Programming Thermoresponsiveness of NanoVelcro Substrates Enables Effective Purification of Circulating Tumor Cells in Lung Cancer Patients. <i>ACS Nano</i> , 2015, 9, 62-70.	14.6	118
3	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. <i>Oncotarget</i> , 2015, 6, 44781-44793.	1.8	94
4	Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. <i>Cancer</i> , 2015, 121, 3240-3251.	4.1	89
5	NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 78-93.	13.7	89
6	Imprinted NanoVelcro Microchips for Isolation and Characterization of Circulating Fetal Trophoblasts: Toward Noninvasive Prenatal Diagnostics. <i>ACS Nano</i> , 2017, 11, 8167-8177.	14.6	68
7	Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications. <i>Advanced Materials</i> , 2020, 32, e1903663.	21.0	66
8	Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. <i>Theranostics</i> , 2016, 6, 1425-1439.	10.0	56
9	Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2052-2061.	6.4	49
10	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. <i>Cancer Research</i> , 2018, 78, 6086-6097.	0.9	49
11	Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700701.	7.6	38
12	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. <i>Theranostics</i> , 2019, 9, 2812-2826.	10.0	20
13	Supramolecular Nanosubstrate-Mediated Delivery for Reprogramming and Transdifferentiation of Mammalian Cells. <i>Small</i> , 2015, 11, 2499-2504.	10.0	12
14	Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. <i>Cancer Medicine</i> , 2018, 7, 4639-4649.	2.8	12
15	Clinical Decision Support for Ovarian Carcinoma Subtype Classification: A Pilot Observer Study With Pathology Trainees. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 869-877.	2.5	7
16	Circulating tumor cells in prostate cancer: beyond enumeration. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 63-73.	0.3	6
17	Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 43-54.	0.4	5
18	Applications of circulating tumor cells for prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 254-259.	1.2	4

#	ARTICLE	IF	CITATIONS
19	RNA Biomarkers: Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection (Adv. Healthcare Mater. 3/2018). Advanced Healthcare Materials, 2018, 7, 1870013.	7.6	3
20	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. Journal of Clinical Oncology, 2021, 39, 167-167.	1.6	1
21	A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. Journal of Clinical Oncology, 2016, 34, 208-208.	1.6	1
22	Development of a circulating tumor cell-based RNA classifier for patients with castration-resistant prostate cancer: CTC-PCS/PAM50.. Journal of Clinical Oncology, 2020, 38, e17509-e17509.	1.6	1
23	Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.. Journal of Clinical Oncology, 2020, 38, 170-170.	1.6	1
24	Circulating Rare Cells: Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications (Adv. Mater. 1/2020). Advanced Materials, 2020, 32, 2070008.	21.0	0
25	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. Journal of Clinical Oncology, 2021, 39, e17008-e17008.	1.6	0
26	Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases.. Journal of Clinical Oncology, 2015, 33, 11027-11027.	1.6	0
27	Very small nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 64-64.	1.6	0
28	A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.. Journal of Clinical Oncology, 2016, 34, e16552-e16552.	1.6	0
29	Very-small-nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis (VM) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, e16530-e16530.	1.6	0
30	Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.. Journal of Clinical Oncology, 2017, 35, 5031-5031.	1.6	0
31	NanoVelcro CTC purification systems for expressional analysis of circulating tumor cells from prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 295-295.	1.6	0
32	Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.. Journal of Clinical Oncology, 2018, 36, e17063-e17063.	1.6	0
33	A noninvasive prognostic biomarker for metastatic castration-resistant prostate cancer: Very small nuclear circulating tumor cells.. Journal of Clinical Oncology, 2019, 37, 179-179.	1.6	0
34	A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 157-157.	1.6	0
35	A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5059-5059.	1.6	0
36	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17512-e17512.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 168-168.	1.6	0
38	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American Journal of Clinical and Experimental Urology, 2021, 9, 350-366.	0.4	0